These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 18644997)

  • 1. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
    Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
    Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
    Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
    J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
    Rusnak DW; Alligood KJ; Mullin RJ; Spehar GM; Arenas-Elliott C; Martin AM; Degenhardt Y; Rudolph SK; Haws TF; Hudson-Curtis BL; Gilmer TM
    Cell Prolif; 2007 Aug; 40(4):580-94. PubMed ID: 17635524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
    Zhang L; Ngo JA; Wetzel MD; Marchetti D
    Neoplasia; 2015 Jan; 17(1):101-13. PubMed ID: 25622903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
    Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
    Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.
    Imami K; Sugiyama N; Imamura H; Wakabayashi M; Tomita M; Taniguchi M; Ueno T; Toi M; Ishihama Y
    Mol Cell Proteomics; 2012 Dec; 11(12):1741-57. PubMed ID: 22964224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RON confers lapatinib resistance in HER2-positive breast cancer cells.
    Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
    Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
    Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
    Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
    Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U
    Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
    Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
    Fabi A; Merola R; Ferretti G; Di Benedetto A; Antoniani B; Ercolani C; Nisticò C; Papaldo P; Ciccarese M; Sperduti I; Vici P; Marino M; Gori S; Botti C; Malaguti P; Cognetti F; Mottolese M
    Expert Opin Pharmacother; 2013 Apr; 14(6):699-706. PubMed ID: 23472669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 signaling regulates HER2 localization and membrane retention.
    Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
    PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.